Therapeutic vaccines for preventing AIDS: Their use with HAART

Lancet

Volumn 353, Issue 9166, 1999, Pages 1723-1724

  Hoff, Rodney ^a   McNamara, James ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; VIRUS REPLICATION;

EID: 0033594728     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)90025-9     Document Type: Note

References (14)

1. Salk J, Bretscher PA, Salk PL, Clerici M, Shearer GM. A strategy for prophylactic vaccination against HIV. Science 1993; 260: 1270-72.
2. Ratto-Kim S, Sitz KV, Garner RP, et al. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the cell proliferative response. J Infect Dis 1999; 179: 337-44.
3. Tsoukas CM, Raboud J, Bernard NF, et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immune deficiency. AIDS Res Human Retrovir 1998; 14: 483-90.
4. Eron JJ, Ashby MA, Giordano MF, et al. Randomized trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996; 348: 1547-51.
5. Klein MR, Veenstra J, Holwerda AM, et al. Gag-specific immune responses after immunization with p17/p24: Ty virus-like particles in HIV type 1-seropositive individuals. AIDS Res Hum Retrovir 1996; 13: 393-99.
6. Tubiana R, Gomard E, Fleury H, et al. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double blind controlled randomized study of safety and immunogenicity. AIDS 1997; 11: 819-20.
7. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients. Lancet 1998; 351: 1320-25.
8. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92-100.
9. Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double blind, adjuvant controlled trial. J AIDS Hum Retrovirol 1995; 10 (suppl 2): S74-82.
10. Churdboonchart V, Moss RB, Sirawaraporn W, et al. Effect of HIV-specific immune based therapy in subjects with HIV-1 subtype E in Thailand. AIDS 1998; 12: 1521-27.
11. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278: 1447-50.
12. Rinaldo CR, Liebmann JM, Huang X-L, et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999; 179: 329-36.
13. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336: 1343-49.
14. Valentine FT, DeGruttola V, Kaplan M, et al. Effects of HAART compared to HAART plus an inactivated HIV immunogen on lymphocyte proliferative responses (LPR) to HIV antigens. Conference Supplement 12th World AIDS Conference, Geneva, June 28-July 3, 1998 abstr LB31227